Evidence map›Paper›PMID 41459415›Full record

ArticleBehavioural neurology2025

Real-World Experience of Sustained-Release Fampridine in Chinese Patients With Multiple Sclerosis: A Case Series on Walking Impairment and Fatigue.

Han Wang, Wenting Zhang, Fengjun Wang, Qin Wang, Tao Yang, Runze Zhao, RongRong Wang, Antonio Carrillo-Vico, Guillermo Izquierdo, Yu Zhang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Behavioural neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Han WangDepartment of Neurology, Yan'an University Medical College No. 3 Affiliated Hospital, Xianyang, Shaanxi, China.ORCID https://orcid.org/0009-0004-6776-5013
Wenting ZhangDepartment of Gastroenterology and Hepatology, Xijing Hospital, Air Force Medical University, Xi'an, Shaanxi, China, fmmu.edu.cn.
Fengjun WangDepartment of Neurology, Yan'an University Medical College No. 3 Affiliated Hospital, Xianyang, Shaanxi, China.
Qin WangCollege of International Cooperation, Xi'an International University, Xi'an, Shaanxi, China, xaiu.edu.cn.
Tao YangDepartment of Endoscopy Center, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China, sysu.edu.cn.ORCID https://orcid.org/0000-0001-5283-7249
Runze ZhaoDepartment of Ophthalmology, Eye Institute of PLA, Xijing Hospital, Air Force Medical University, Xi'an, Shaanxi, China, fmmu.edu.cn.
RongRong WangDepartment of Neurology, Yan'an University Medical College No. 3 Affiliated Hospital, Xianyang, Shaanxi, China.ORCID https://orcid.org/0009-0009-0382-1561
Antonio Carrillo-VicoDepartment of Neurology, Instituto de Biomedicina de Sevilla, IBiS (Universidad de Sevilla, HUVR, Junta de Andalucía, CSIC), Sevilla, Andalusia, Spain, ibis-sevilla.es.ORCID https://orcid.org/0000-0002-8516-0999
Guillermo IzquierdoDepartment of Neurology, Hospital Vithas Nisa Sevilla, Sevilla, Andalusia, Spain.
Yu ZhangDepartment of Medical Affairs, ER-Biomed (Shanghai) Pharmaceutical Technology Co., Ltd, Shanghai, China.
Xiongfei ZhaoDepartment of Neurology, Yan'an University Medical College No. 3 Affiliated Hospital, Xianyang, Shaanxi, China.ORCID https://orcid.org/0009-0003-1358-376X
Guoxun ZhangDepartment of Neurology, Yan'an University Medical College No. 3 Affiliated Hospital, Xianyang, Shaanxi, China.ORCID https://orcid.org/0000-0002-7709-3925

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To investigate the efficacy of sustained-release fampridine tablets (fampridine-SR) on walking impairment and fatigue on Chinese patients with multiple sclerosis (MS). Methods: All patients ( Results: The baseline EDSS score was 4.67 ± 0.36. Fampridine-SR significantly decreased the EDSS score by 0.63 ± 0.20 ( Conclusion: Fampridine-SR was a fast-acting oral potassium channel blocker on improving walking ability of MS as early as day 1. It demonstrated the positive effects on walking impairment and fatigue, including the physical, cognitive, and psychosocial subscales of MFIS, in Chinese patients with MS.

Indexed as

4-AminopyridineFatigueMultiple SclerosisPotassium Channel BlockersAdultChinaDelayed-Action PreparationsDisability EvaluationEast Asian PeopleFemaleHumansMaleMiddle AgedTreatment OutcomeWalking4-AminopyridineDelayed-Action PreparationsPotassium Channel Blockersfatiguemultiple sclerosissustained-release fampridine tabletswalking impairment

Identifiers

PMID41459415
PMCPMC12740591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.